Researchers over the world are discovering ideal materials with favorable biocompatibility for valved conduits to treat congenital heart disease. Blood compatibility should be fundamentally considered for vascular devices. At present, autologous pericardium shows the best blood compatibility. Therefore, we employed the autologous pericardium as a control (control group) to compare and explore the in vitro and in vivo blood compatibility of a novel Chinese valved bovine pericardium patch with superior fatigue durability and diverse types (treatment group). Both patches were implanted into small fat- tail sheep to replace the antetheca of right ventricular outflow tract (RVOT) and pulmonary trunk through surgery. All animals survived to the predetermined time without any complications. Operation time, cardiopulmonary bypass time, and aortic cross clamp time in the control group were significantly longer than those in the treatment group (P < 0.05). Good healing status in the both planted areas was observed without any thrombosis or infarction. There was no significant difference in In vivo blood compatibility indicators including red blood cells injury, blood routine, and thrombosis which were investigated by free hemoglobin (HGB) determination, automatic blood cell analyzer, and naked eye/microscope observation, respectively (P > 0.05). Results of in vitro compatibility indexes including hemolysis, complement activation, plasma soluble P-selectin, and dynamic clotting which were evaluated through spectrophotometry and ELISA kits were also exactly similar between the two groups (P > 0.05). Therefore, this Chinese patch exhibited wonderful blood compatibility and might be developed as a medical device for RVOT reconstruction.